ReviewFrontiers in bioengineering and biotechnology2020
Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease.
Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Research trends of nanotechnology in coronary heart disease: a bibliometric analysis from 2012 to 2025.Frontiers in pharmacology · 2026Pooled it
- "Microbial metabolites in cardioprotection: an immune-engineered framework for heart failure and post-ischemic remodeling: a narrative review".Annals of medicine and surgery (2012) · 2026Review
- Nanomedicine for Cardiac Repair in Heart Failure: From Targeted Delivery to Regenerative Modulation.International journal of nanomedicine · 2026Review
- Development of Curcumin-Loaded Hybrid Lipid-Polymeric Nanoparticles for Hypoxia-Related Applications.International journal of nanomedicine · 2026Article
- Bromelain-functionalized omega-3 nanocarriers for targeted icariin delivery: a multifunctional shield for cardiac repair in doxorubicin-induced injury.Journal of materials science. Materials in medicine · 2025Article
- Endosomal Mechanisms in Heart Failure Pathophysiology.Current heart failure reports · 2025Review
- Engineering Nanoparticles and Bioscaffolds for Targeted microRNA Delivery in Cardiovascular Regeneration-A Comprehensive Review.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Review
- The future of cardiac repair: a review on cell-free nanotherapies for regenerative myocardial infarction.Drug delivery and translational research · 2025Review
- Nanotechnology Innovations in Myocardial Infarction: Diagnosis, Treatment and the Way Forward.Journal of cardiovascular translational research · 2025Review
- Anti-inflammatory Therapies for Ischemic Heart Disease.Current cardiology reports · 2025Review
- Emerging Gene Therapy Based on Nanocarriers: A Promising Therapeutic Alternative for Cardiovascular Diseases and a Novel Strategy in Valvular Heart Disease.International journal of molecular sciences · 2025Review
- Iron chelators loaded on myocardiocyte mitochondria-targeted nanozyme system for treating myocardial ischemia-reperfusion injury in mouse models.Journal of nanobiotechnology · 2025Article
- The Emergence of Nanotechnology in the Prognosis and Treatment of Myocardial Infarctions.Recent patents on nanotechnology · 2025Review
- Article
- Review
- Nanoparticles as Drug Delivery Systems for the Targeted Treatment of Atherosclerosis.Molecules (Basel, Switzerland) · 2024Review
- Targeting cardiomyocyte cell cycle regulation in heart failure.Basic research in cardiology · 2024Review
- Autophagy and mitophagy as potential therapeutic targets in diabetic heart condition: Harnessing the power of nanotheranostics.Asian journal of pharmaceutical sciences · 2024Review
- Review
- Inflammation-Responsive Micellar Nanoparticles from Degradable Polyphosphoramidates for Targeted Delivery to Myocardial Infarction.Journal of the American Chemical Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
The regenerative capacity of an adult cardiac tissue is insufficient to repair the massive loss of heart tissue, particularly cardiomyocytes (CMs), following ischemia or other catastrophic myocardial injuries. The delivery methods of therapeutics agents, such as small molecules, growth factors, exosomes, cells, and engineered tissues have significantly advanced in medical science. Furthermore, with the controlled release characteristics, nanoparticle (NP) systems carrying drugs are promising in enhancing the cardioprotective potential of drugs in patients with cardiac ischemic events. NPs can provide sustained exposure precisely to the infarcted heart via direct intramyocardial injection or intravenous injection with active targets. In this review, we present the recent advances and challenges of different types of NPs loaded with agents for the repair of myocardial infarcted heart tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.